Fresh analysis reveals that individuals who come off popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle programs.
Research printed in a leading health publication shows that while obese individuals can lose about a fifth of their body weight while on the medication, the weight returns at an average rate of nearly a kilo each month once they quit.
"People using such medications should be cognizant of the potential of rapid rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about 18 months.
Weighing Treatments
The research, which examined dozens of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone typically see a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Quick Regain
Nutrition scientists suggest the mode of action of the injections explains the heightened regain.
The injections mimic a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication means appetite is uncontrolled, making binge eating much more probable."
A Chronic Issue?
The NHS suggest the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians say that, due to the significant potential of weight regain, the therapy might need to be ongoing.
This view is supported by drug manufacturers, who say that the findings "highlight the long-term nature of excess weight," similar to managing conditions like hypertension.
User Testimonies
Users who have come off the medication report a sudden resurgence of appetite.
"I experienced a trigger activating and I was suddenly ravenous," described an individual.
The struggle is exacerbated if users have not adopted permanent dietary or behavioural changes during treatment.
Significant Interest
Survey data show that millions of people in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is greater among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a magic fix and lasting health benefits relies on integrated lifestyle changes.
